ImmunoMet Therapeutics is a clinical-stage oncology company developing lixumistat (IM156), a best-in-class OxPhos inhibitor that targets the metabolic dependency driving cancer-cell survival in resistant tumours.
59% of cancers have no actionable target, leaving patients with few effective treatment options.
When cancers develop resistance to standard therapies, many rewire their metabolism to rely on oxidative phosphorylation (OxPhos) for survival.
Lixumistat targets OxPhos dependency directly, exploiting a vulnerability in resistant tumours.
Explore the Science →
The Phase 1b/2a trial at MD Anderson Cancer Center has shown encouraging early results with lixumistat, given in combination with standard of care in patients with advanced pancreatic cancer.
Best-in-class mechanism, an established recommended Phase 2 dose, and early efficacy signals in one of oncology's hardest indications. We'd welcome a conversation about partnering and investment.
